Development and Validation of Nomograms to Predict Outcome Following LuPSMA Radionuclide Treatment for Metastatic Castration-Resistant Prostate Cancer: A Multicenter International Study

Castration Resistant ◽

Development And Validation

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer

European Journal of Cancer ◽

10.1016/j.ejca.2021.02.042 ◽

2021 ◽

Vol 150 ◽

pp. 83-94

Author(s):

H.I. Scher ◽

A.J. Armstrong ◽

J.D. Schonhoft ◽

A. Gill ◽

J.L. Zhao ◽

...

Keyword(s):

Prostate Cancer ◽

Tumour Cell ◽

Prognostic Biomarker ◽

Castration Resistant ◽

Circulating Tumour Cell ◽

Cell Enumeration ◽

Development And Validation

Treatment patterns among men with metastatic Castration Resistant Prostate Cancer (mCRPC): Results from a European international study

European Urology Open Science ◽

10.1016/s2666-1683(21)03141-4 ◽

2021 ◽

Vol 33 ◽

pp. S288-S289

Author(s):

P. Barata ◽

A. Leith ◽

A. Ribbands ◽

R. Montgomery ◽

M. Last ◽

...

Keyword(s):

Prostate Cancer ◽

International Study ◽

Treatment Patterns ◽

Development and validation of a prognostic model for overall survival in chemotherapy-naïve men with metastatic castration-resistant prostate cancer

Annals of Oncology ◽

10.1093/annonc/mdy406 ◽

2018 ◽

Vol 29 (11) ◽

pp. 2200-2207 ◽

Cited By ~ 12

Author(s):

A.J. Armstrong ◽

P. Lin ◽

C.S. Higano ◽

C.N. Sternberg ◽

G. Sonpavde ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Prognostic Model ◽

Castration Resistant ◽

Development And Validation

Neuroendocrine secretory profiles are not associated with treatment response to Lu-177-PSMA-617 radioligand therapy in patients with advanced metastatic castration-resistant prostate cancer

10.1055/s-0040-1708342 ◽

2020 ◽

Author(s):

T Derlin ◽

R Werner ◽

C Henkenberens ◽

TL Ross ◽

FM Bengel

Keyword(s):

Prostate Cancer ◽

Treatment Response ◽

Radioligand Therapy ◽

Prostate specific membrane antigen targeted radioligand therapy of metastatic castration-resistant prostate cancer using Lu-177 PSMA-617: safety, efficacy and dosimetry in comparison with Lu-177 PSMA I&T

Endocrine Abstracts ◽

10.1530/endoabs.47.oc32 ◽

2016 ◽

Author(s):

Harshad R. Kulkarni ◽

Aviral Singh ◽

Christiane Schuchardt ◽

Karin Niepsch ◽

Richard P. Baum

Keyword(s):

Prostate Cancer ◽

Prostate Specific Membrane Antigen ◽

Radioligand Therapy ◽

Castration Resistant ◽

Specific Membrane

New combination therapies for castration-resistant prostate cancer

Oncology Abstracts ◽

10.1530/oncolabs.1.p031 ◽

2019 ◽

Author(s):

Mitchell G Lawrence ◽

Laura H Porter ◽

Daisuke Obinata ◽

Shahneen Sandhu ◽

Luke A Selth ◽

...

Keyword(s):

Prostate Cancer ◽

New Combination ◽

Combination Therapies ◽

The role of microbiota in driving castration-resistant prostate cancer

10.26226/morressier.5f69edb69b74b699bf38c5cf ◽

2020 ◽

Author(s):

Arianna Calcinotto

Keyword(s):

Prostate Cancer ◽

FDA approves darolutamide for non-metastatic castration-resistant prostate cancer

Case Medical Research ◽

10.31525/cmr-1904aca ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Case Medical Research ◽

10.31525/ct1-nct03851640 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽

Efficacy And Safety ◽

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer

Case Medical Research ◽

10.31525/ct1-nct03874884 ◽

2019 ◽

Author(s):

Keyword(s):

Prostate Cancer ◽